XELLIA PHARMACEUTICALS ApS: Financial statements 2015
CVR: 61094628
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2015. In 2015, the company reported revenue of DKK 1,215,664,000 and a net result of DKK -74,009,000. The profit margin was -6.1%. Equity in the 2015 report amounted to DKK 729,235,000. The solvency ratio was 43.1%. The company had 479 employees in the financial year.
- Revenue
- DKK 1,215,664,000
- Gross Profit
- DKK 364,177,000
- Profit/Loss
- DKK -74,009,000
- Equity
- DKK 729,235,000
- Total Assets
- DKK 1,693,521,000
- Employees
- 479
Official annual report
How creditworthy is XELLIA PHARMACEUTICALS ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
XELLIA PHARMACEUTICALS ApS has published its annual report for 2014.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.